Tempest Therapeutics (FRA:3OS0) Volatility: N/A% (As of Jul. 02, 2026)


FRA:3OS0 Tempest Therapeutics Inc FRA:3OS0
32 GF Score
Price €5.82
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Volatility?

Tempest Therapeutics FRA:3OS0 32 Volatility is N/A% as of Jul. 02, 2026. GuruFocus rates FRA:3OS0 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Tempest Therapeutics does not have enough data to calculate Volatility.

Tempest Therapeutics  (FRA:3OS0) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Tempest Therapeutics Volatility Related Terms

FRA:3OS0 vs HOWL, INTI, GTBP: Volatility Comparison

For the Biotechnology subindustry, Tempest Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Volatility falls into.


FRA:3OS0
32GF Score
Tempest Therapeutics Inc FRA:3OS0
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics  (FRA:3OS0) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of N/A% mean?
Tempest Therapeutics (FRA:3OS0) has a Volatility of N/A% as of Jul. 02, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Volatility too high?
Tempest Therapeutics' current Volatility is N/A%. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Volatility compare to HOWL and INTI?
Tempest Therapeutics' Volatility of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Volatility is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (FRA:3OS0) has a current Volatility of N/A%. The current Volatility is N/A%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Tempest Therapeutics (FRA:3OS0), the current Volatility is N/A% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Other Exchanges TPST:USA
Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for FRA:3OS0

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.82
Price